CRx-191

A topical dissociated steroid providing the efficacy of a high-potency topical steroid with a mid-potency steriod safety profile.

• Description: Synergistic combination of the tricyclic antidepressant nortriptyline and the glucocorticoid steroid mometasone for the treatment of psoriasis and other steroid-responsive dermatoses.
• Data: Demonstrated preclinical efficacy in a number inflammation models, including psoriasis.
• Formulation: Novel topical cream co-formulation completed.
• Commercial Opportunity: Psoriasis and potential expansion into other steroid-responsive dermatoses.

There are 6.7 million patients with psoriasis in the U.S.

Status: In Phase 2a study.

CRx-191 is a selective steroid amplifier containing a mid-potency steroid, mometasone, and the anti-depressant, nortriptyline. We believe CRx-191 works through a novel mechanism of action in which nortriptyline amplifies mometasone's anti-inflammatory activities without enhancing steroid side effects such as skin atrophy. CRx-191 has demonstrated efficacy in multiple experimental and preclinical models of inflammation, including psoriasis. We have developed a novel topical formulation of CRx-191 for use in planned proof-of-concept clinical trials, as a topical commercial formulation of nortriptyline has not been previously created.